{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:31:06Z","timestamp":1792794666058,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004851","name":"New York City Department of Health and Mental Hygiene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jsat.2020.108272","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T01:04:00Z","timestamp":1610931840000},"page":"108272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"special_numbering":"C","title":["Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic"],"prefix":"10.1016","volume":"124","author":[{"given":"Linda","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Bogel","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy L.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jsat.2020.108272_bb0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison\u2014a high risk of death for former inmates","volume":"356","author":"Binswanger","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2020.108272_bb0010","unstructured":"Drug Enforcement Agency. Letter to DEA qualifying practitioners. https:\/\/www.deadiversion.usdoj.gov\/GDP\/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf. Published 2020, March 31. Accessed April 15, 2020."},{"key":"10.1016\/j.jsat.2020.108272_bb0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2017.01.048","article-title":"The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting","volume":"176","author":"Eibl","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2020.108272_bb0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","article-title":"Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system","volume":"75","author":"Green","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.jsat.2020.108272_bb0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City","volume":"40","author":"Hansen","year":"2013","journal-title":"Journal of Behavioral Health Services and Research"},{"key":"10.1016\/j.jsat.2020.108272_bb0030","series-title":"Low barrier tele-buprenorphine in the time of COVID-19: A case report","author":"Harris","year":"2020"},{"issue":"9","key":"10.1016\/j.jsat.2020.108272_bb0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2020.108272_bb0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsat.2019.03.007","article-title":"Telemedicine-delivered treatment interventions for substance use disorders: A systematic review","volume":"101","author":"Lin","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2020.108272_bb0045","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/add.13779","article-title":"Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England","volume":"112","author":"Marsden","year":"2017","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.jsat.2020.108272_bb0050","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1360-0443.2010.02990.x","article-title":"Meta-analysis of drug-related deaths soon after release from prison","volume":"105","author":"Merrall","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2020.108272_bb0055","author":"Nouri"},{"issue":"12","key":"10.1016\/j.jsat.2020.108272_bb0060","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1007\/s11606-020-05633-4","article-title":"Association between patient portal use and broadband access: A national evaluation","volume":"35","author":"Rodriguez","year":"2020","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2020.108272_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108011","article-title":"Appointment wait-times and arrival for patients at a low-barrier access addiction clinic","volume":"114","author":"Roy","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2020.108272_bb0070","author":"TREATs Act, S.4103, 116th Cong"},{"issue":"2","key":"10.1016\/j.jsat.2020.108272_bb0075","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/ADM.0000000000000287","article-title":"Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: A 2-year retrospective data analysis","volume":"11","author":"Zheng","year":"2017","journal-title":"Journal of Addiction Medicine"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220305298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220305298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:53:18Z","timestamp":1760039598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547220305298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":15,"alternative-id":["S0740547220305298"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108272","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108272"}}